Survival after breast cancer treatment: the impact of provider volume

J Eval Clin Pract. 2007 Oct;13(5):749-57. doi: 10.1111/j.1365-2753.2006.00748.x.

Abstract

Background: Research has not paid sufficient attention to the need for adequate case-mix adjustment in studies of the relationship between provider volume and performance. This study attempted to address this limitation by capturing and including 5-year survival outcomes and a wide range of case-mix variables in multivariate analyses of the volume-outcome relationship relating to breast cancer treatments.

Methods: All patients diagnosed with invasive primary breast cancer during 1996 (n = 809) were included. Patient, disease and treatment data were extracted from medical records; survival data were corroborated using official death registrations. A Cox proportional hazards approach was used to model relationships between patient, disease and service variables and risk of death.

Results: There were 262 deaths among 807 patients followed up; overall 5-year survival was 70%. Advancing age, higher levels of co-morbidity, late-stage disease, more positive nodes, and high-grade tumour were independently associated with lower survival (P < 0.05). Patients who received hormonal therapy (HR 0.50, 95% CI 0.28-0.89) and radiotherapy (HR 0.73, 95% CI 0.53-1.03) had a survival advantage. Using a cut-off point of > or =30 cases per annum, survival was lower for patients treated in low volume settings (HR 1.47, 95% CI 1.09-1.96) after adjustment for case mix.

Conclusions: There was some evidence to support treatment in high volume settings although patient and disease variables were the major determinants of survival for patients with breast cancer.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Age Factors
  • Aged
  • Aged, 80 and over
  • Antineoplastic Agents, Hormonal / therapeutic use
  • Breast Neoplasms / mortality*
  • Breast Neoplasms / pathology
  • Breast Neoplasms / therapy*
  • Combined Modality Therapy
  • Female
  • Humans
  • Menopause / physiology
  • Middle Aged
  • Practice Patterns, Physicians' / statistics & numerical data*
  • Proportional Hazards Models
  • Risk Adjustment
  • Severity of Illness Index
  • Socioeconomic Factors
  • Survival Rate

Substances

  • Antineoplastic Agents, Hormonal